SequelSEC

INTELLIGENT BIO SOLUTIONS INC. INBS

Surgical & Medical Instruments & Apparatus · CIK 0001725430 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$4.22M
Fiscal year ended 2026-06-30
Operating income
-$12.55M
Fiscal year ended 2026-06-30
Free cash flow
-$12.05M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$11.71MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$3.87Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2026-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin-285.9%16th
Operating margin-299.1%17th
Net margin-294.9%19th
Revenue YoY growth38.1%81th
Current ratio1.44x23th
Gross margin48.6%28th
SBC / revenue4.6%45th
CapEx / revenue3.0%48th

INTELLIGENT BIO SOLUTIONS INC. (INBS) reported revenue of $4.22M and net income of -$12.43M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from INTELLIGENT BIO SOLUTIONS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

INTELLIGENT BIO SOLUTIONS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.22M
Cost of revenue$2.17M
Gross profit$2.05M
Operating income-$12.55M
Net income-$12.43M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

INTELLIGENT BIO SOLUTIONS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$3.99M
Total assets$11.94M
Current assets$7.10M
Total liabilities$6.65M
Current liabilities$4.93M
Total equity incl. NCI$5.29M
Temporary (mezzanine) equityUnavailable
Inventory$418.58K
Accounts receivable$848.46K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$712.45K

Cash flow

INTELLIGENT BIO SOLUTIONS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.93M
Capital expenditures$125.73K
Investing cash flow-$85.57K
Financing cash flow$14.98M
Net change in cash$2.97M
Stock-based compensation$195.21K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.12M

Derived

INTELLIGENT BIO SOLUTIONS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$12.05M
Gross margin48.6%
Operating margin-297.8%
FCF margin-285.9%
SBC / revenue4.6%
Current ratio1.44x
Revenue YoY growth38.1%
Net margin-294.9%
R&D / revenueUnavailable
CapEx / revenue3.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INBS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K/A · Filed 2026-10-21View SEC filing
10-K · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-K · Filed 2025-08-15View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.